Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant relatlimab + nivolumab versus nivolumab after complete resection of stage III-IV melanoma
CTR20220635Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Relatlimab + nivolumab fixed-dose combination with Nivolumab monotherapy (2 arms). Primary endpoint: recurrence-free survival. Started Jun 2022; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20220635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220635.